Impact of Dietary Guidance and Probiotics in the Treatment of Endometriosis and Irritable Bowel Syndrome in Women

Inclusion Criteria: 1. Women between 18 and 50 years of age who wish to participate in the clinical trial; 2. Willingness to voluntarily participate in the study and accept randomization to any of the three treatment arms; 3. Participating exclusively in this clinical trial during the study period; 4. Signing the Informed Consent Form (ICF) approved by the Research Ethics Committee (CEP) and CONEP Exclusion Criteria: 1. Chronic, severe, or uncompensated clinical conditions, such as: malnutrition (BMI \<18); insulin-dependent diabetes (types 1 or 2); uncontrolled hypertension; lung disease such as asthma or other chronic obstructive pulmonary disease; hematologic and liver diseases; advanced-stage chronic kidney disease (grades 3, 4, and 5); metabolic disorders; and immunosuppression; 2. Clinical conditions of the gastrointestinal tract that cause IBS-like symptoms, such as: inflammatory bowel disease (Chron's disease, ulcerative colitis), microscopic colitis, celiac disease, and lactose intolerance; 3. Endometriosis requiring surgical treatment during the study period; 4. Severe eating disorders, such as: bulimia, anorexia nervosa, and binge-eating disorder; 5. Chronic use of any medication with potential interaction with probiotics, the intestinal microbiota, or the natural progression of the disease in the last 6 months (such as probiotics, antibiotics, antifungals, antihistamines, digestive medications, or treatments for constipation or diarrhea); 6. Patients who already consume healthy foods or are on a restrictive diet more than four days a week, which may affect the evaluation results; 7. Patients whose stool protopastological examination is altered; 8. Inability to use oral medication; 9. Pregnancy or lactation; 10. History of alcohol or drug dependence; 11. Smoking in the last three years; 12. Inability to cooperate with investigators due to cognitive impairment or mental state.